ClinicalTrials.gg
CompletedNCT07787624Updated Oct 28, 2026

Phase 1 Clinical Study of MWN109 Injection in Healthy Chinese Volunteers

A Phase 1 interventional study of MWN109 and MWN109 in Healthy Volunteers, sponsored by Shanghai Minwei Biotechnology Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Shanghai Minwei Biotechnology Co., Ltd (part of Lepu Medical) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Dec 2024, registered Aug 2026).
Updated Oct 28, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a randomized, double-blind, placebo-controlled, single- and multiple- dose-escalating Phase 1a study. The objective is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of MWN109 Injection in healthy Chinese volunteers and to provide data for subsequent clinical trials.

The study includes a single ascending dose (SAD) part with 4 dose cohorts and a multiple ascending dose (MAD) part with 3 dose cohorts, using a 3-week dose titration regimen.

Approximately 58 volunteers will be enrolled. The primary endpoint is safety, assessed by adverse events, serious adverse events, vital signs, physical examinations, laboratory tests, and 12-lead electrocardiograms. The secondary endpoint is the pharmacokinetic characteristics.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Shanghai Minwei Biotechnology Co., Ltd is the lead sponsor of 21 studies on the registry; 10 are open to participants now.

First submitted after Shanghai Minwei Biotechnology Co., Ltd became part of Lepu Medical.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 28, 2026. See what changed

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants aged 18 to 45 years (inclusive) at the time of signing the form (ICF); the proportion of either gender shall not be less than 1/3.
  2. Male participants with body weight not less than 50 kg, female participants with body weight not less than 45 kg; (BMI) within 19.0 to 28.0 kg/m\^2 (inclusive).
  3. From the time of signing the informed consent form (ICF) until 3 months after the last dose, participants must have no plans to become pregnant or to father a child, must agree to use effective measures to prevent pregnancy or causing a partner to become pregnant, and must have no plans to donate sperm or eggs.

Exclusion criteria

Exclusion Criteria:

  1. History of severe drug allergy (especially known or suspected allergy to the of MWN109 Injection) or severe atopic allergic diseases/history (asthma, urticaria, eczematous dermatitis, etc.) or severe allergic constitution (allergy to two or more foods or drugs) (by inquiry).
  2. History of acute or chronic pancreatitis, symptomatic gallbladder disease, pancreatic injury or other high-risk factors that may lead to pancreatitis, or serum amylase > 1.5 × (ULN) at screening (by inquiry and examination).
  3. Family history or history of medullary thyroid C-cell tumor/carcinoma; history of thyroid dysfunction or abnormal thyroid hormone levels (by inquiry).
  4. History or presence at screening of digestive system diseases that may increase the risk to volunteers, such as pancreatitis, abnormal gastric emptying (e.g., gastroparesis, pyloric stenosis, pyloric obstruction, etc.), or severe chronic gastrointestinal diseases (e.g., history of intestinal obstruction, active ulcer within 6 months) (by inquiry).
  5. History of infectious diseases (which, in the investigator's assessment, may significantly affect the safety evaluation of volunteers) or severe trauma within 4 weeks before screening, or major surgery within 3 months before screening (by inquiry and examination).
  6. Use of any prescription or over-the-counter drug (including chemical drugs, vitamins, herbal medicines, etc.) within 2 weeks before dosing (by inquiry and examination);
  7. History of substance abuse (by inquiry).
  8. Blood donation or massive blood loss (> 400 mL) or blood transfusion within 3 months before screening (by inquiry).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    MWN109 S

    MWN109 Cohort S consists of 4 dose groups. Healthy volunteers in all dose groups were randomly assigned to receive a single subcutaneous dose of MWN109 or placebo.

    Drug: MWN109 · Drug: Placebo

  • Experimental
    MWN109 M

    MWN109 Cohort M consists of 3 dose groups. In all dose groups, healthy volunteers are randomized to receive subcutaneous injections of MWN109 or placebo with weekly titration dosing for a total of 3 administrations.

    Drug: MWN109 · Drug: Placebo

Interventions

  • DrugMWN109

    S1, S2 S3, S4; administered subcutaneously (SC)

  • DrugMWN109

    M1, M2, M3; administered SC

  • DrugPlacebo

    administered SC

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs)

    The incidence of adverse events (AEs) and serious adverse events (SAEs).

    Time frame: From Day 1 to Day 43

Secondary outcomes

  1. Maximum Concentration (Cmax)

    Cmax of MWN109.

    Time frame: From Day 1 to Day 29

  2. Time to Reach Maximum Concentration (Tmax)

    Tmax of MWN109.

    Time frame: From Day 1 to Day 29

  3. Area Under the Curve From Time 0 to Last Quantifiable Time Point (AUC0-t)

    AUC0-t of MWN109.

    Time frame: From Day 1 to Day 29

  4. Area Under the Curve From Time 0 to Infinity (AUC0-inf)

    AUC0-inf of MWN109.

    Time frame: From Day 1 to Day 29

  5. Elimination Half-Life (t1/2)

    t1/2 of MWN109.

    Time frame: From Day 1 to Day 29

  6. Steady State Maximum Concentration (Cmax,ss)

    Cmax,ss of MWN109.

    Time frame: From Day 1 to Day 43

  7. Steady State Minimum Concentration (Cmin,ss)

    Cmin,ss of MWN109.

    Time frame: From Day 1 to Day 43

  8. Steady State Concentration (Cav,ss)

    Cav,ss of MWN109.

    Time frame: From Day 1 to Day 43

  9. Time to Reach Maximum Concentration at Steady State (Tmax,ss)

    Tmax,ss of MWN109.

    Time frame: From Day 1 to Day 43

  10. Steady State Apparent Terminal Elimination Half-life (t1/2,ss)

    t1/2,ss of MWN109.

    Time frame: From Day 1 to Day 43

  11. Area Under Concentration-time Profiles during a Dose Interval (AUC0-τ,ss)

    AUC0-τ,ss of MWN109.

    Time frame: From Day 1 to Day 43

  12. Steady State Area Under the Curve From Time 0 to Last Quantifiable Time Point (AUC0-t,ss)

    AUC0-t,ss of MWN109.

    Time frame: From Day 1 to Day 43

07

Study locations

1 site
  • The First Affiliated Hospital of Yunnan University of Chinese Medicine (Yunnan Provincial Hospital of Traditional Chinese Medicine)
    Kunming, Yunnan, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in Jul 2025, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2026
First posted
Aug 26, 2026
StartActual
Dec 18, 2024
Primary completionActual
Jul 20, 2025
CompletionActual
Jul 20, 2025
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
3 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedMale or female participants aged 18 to 6545 years (inclusive) at the time of signing the informed consent form (ICF); the proportion of either gender shall not be less than 1/3.
  • EditedMale participants with body weight not less than 50 kg, female participants with body weight not less than 45 kg; body mass index (BMI) within 2019.0 to 4028.0 kg/m\^2 (inclusive).
  • ChangedBefore Female participants must have no plans for pregnancy or egg donation from 14 days before the first dose to 6 months after the last dose and must agree to use effective contraceptive measures to avoid pregnancy; male participants must have no plans for fathering a child or sperm donation from the first dose to 6 months after the last dose and must agree to use effective contraceptive measures to avoid causing partner pregnancy.Now From the time of signing the informed consent form (ICF) until 3 months after the last dose, participants must have no plans to become pregnant or to father a child, must agree to use effective contraceptive measures to prevent pregnancy or causing a partner to become pregnant, and must have no plans to donate sperm or eggs.
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Eligibility 3 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedMale or female participants aged 18 to 6545 years (inclusive) at the time of signing the informed consent form (ICF); the proportion of either gender shall not be less than 1/3.
    • EditedMale participants with body weight not less than 50 kg, female participants with body weight not less than 45 kg; body mass index (BMI) within 2019.0 to 4028.0 kg/m\^2 (inclusive).
    • ChangedBefore Female participants must have no plans for pregnancy or egg donation from 14 days before the first dose to 6 months after the last dose and must agree to use effective contraceptive measures to avoid pregnancy; male participants must have no plans for fathering a child or sperm donation from the first dose to 6 months after the last dose and must agree to use effective contraceptive measures to avoid causing partner pregnancy.Now From the time of signing the informed consent form (ICF) until 3 months after the last dose, participants must have no plans to become pregnant or to father a child, must agree to use effective contraceptive measures to prevent pregnancy or causing a partner to become pregnant, and must have no plans to donate sperm or eggs.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07787624
Responsible party
Sponsor
First posted
Aug 26, 2026
Start date
Dec 18, 2024
Primary completion
Jul 20, 2025
Completion
Jul 20, 2025
Last update
Oct 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MWN109

Start the discussion